Georg Boonen – CEO, Max Zeller
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
Intergenerika is Swiss generics association, comprising six companies.
Reimbursable generics achieved sales of 637 million Swiss francs in 2015. Compared with the previous year, the growth amounted to more than seven percent.
The Swiss generics market still has room for further growth and development. In terms of value, the total share of generics within the Swiss pharmaceutical market was 19 percent in 2015 in terms of value, and 32 percent by volume. The member companies of Intergenerika are working hard on the educational front to ensure that pharmacists, doctors and patients have a more balanced view of generics.3
Contact
Telephone +41 61 927 64 08
Altmarktstrasse 96
4410 Liestal
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and…
From regenerating damaged muscles to rewriting the cell manufacturing playbook, Switzerland’s next wave of biotech innovators is turning regenerative medicine into a precision science. Once considered futuristic, technologies like autologous…
Currently supplying high-quality medicines to approximately 1 billion patients around the world annually, few pharmaceutical companies straddle both scale and innovation as deliberately as Viatris. In Switzerland – a market…
Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on…
Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences…
Thomas Bohn has led the Greater Geneva Bern area (GGBa) investment agency for over a decade, shaping Switzerland’s strategy to attract global life sciences firms. He focuses on quality over…
Daniel Palmacci, Head of Specialized Modalities at Lonza, combines entrepreneurial vision with deep technical expertise in advanced therapeutics manufacturing. With experience spanning chemical engineering, international operations, and biotechnology development across…
Neurim Pharmaceuticals is a research-driven pharmaceutical company dedicated to advancing science in central nervous system disorders, with a strong emphasis on sleep-related conditions. Carolin Hillebrand, Country Manager of Switzerland and…
Founded in 1971, the Helmut Horten Foundation has steadily evolved from a discreet philanthropic entity into a pivotal force within Switzerland’s medical research landscape. Today, under the leadership of Alain…
Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in…
Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine…
See our Cookie Privacy Policy Here
